“We had several drugs for clinical trials that we were importing into China from overseas. However, the recent tariff increases posed significant challenges,” said Xing. “At that point, we were uncertain how to proceed, as the substantial rise in tariff and VAT expenses - on top of the already high base prices - created a considerable financial burden for our company.”During a panel discussion at the conference, Fiona Xing, Senior Director of Global Clinical Trial Supply at biotech Brii Biosciences shared a ...